|Application ||WB, IHC|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||46302 Da|
|Other Names||cAMP-dependent protein kinase type II-beta regulatory subunit, PRKAR2B|
|Target/Specificity||A synthetic peptide corresponding to residues near the N-terminus of human PKA, RIIb was used as an immunogen.|
|Format||50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||PKA, RIIb Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signaling in cells. Type II regulatory chains mediate membrane association by binding to anchoring proteins, including the MAP2 kinase.|
|Cellular Location||Cytoplasm. Cell membrane. Note=Colocalizes with PJA2 in the cytoplasm and at the cell membrane|
|Tissue Location||Four types of regulatory chains are found: I- alpha, I-beta, II-alpha, and II-beta. Their expression varies among tissues and is in some cases constitutive and in others inducible|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
PKA, RII is one of several regulatory subunits of the cAMP-dependent protein kinase (PKA). The kinase holoenzyme consists of two dimmers of two regulatory (R) and two catalytic (C) subunits that dissociate upon the binding of two cAMP molecules to each of the R subunits (1). Two families of R subunits (RI and RII) have been identified, each possessing distinct cAMP binding properties and resulting in different phosphorylation states (2, 3). The PKA, RII beta (RIIb) regulatory isoform is abundant in brown and white adipose tissue and brain, with limited expression elsewhere. PKA, RIIb is demonstrated to play a role in regulating energy balance and adiposity, thus making it a potential target for therapeutic intervention in obesity (4, 5). It has been shown that PKA, RIIb is essential for cAMP-induced growth inhibition and differentiation of HL-60 human leukemia cells. By binding to its ligand, cAMP, the PKA, RIIb cAMP receptor acts as a tumor suppressor protein exerting growth inhibition, differentiation, and reverse transformation (6).
1. Levy, F. O., et al. Molec. Endocr. 2: 1364-1373, 1988
2. Beebe, S.J., et al. Semin Cancer Biol. 5: 285
3. Braun, R.K, et al. Arch Biochem Biophys. 289: 187
4. Cummings DE, et al. Naure 382(6592):622-6, 1996
5. D. E. Danley, et al. Acta Cryst. D56, 1038-1041, 2000
6. G Tortora, et al. Cell Growth & Differentiation 5(7):753-759, 1994
If you have any additional inquiries please email technical services at email@example.com.